Today: 21 May 2026
Browse Category

Pharmaceutical Industry 26 September 2025 - 27 October 2025

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics shares plunged nearly 45% Monday after the company halted two Phase 3 trials of its CRISPR therapy NTLA-2001 due to a severe liver injury in a patient. The stock dropped from about $19 to the low teens, with CRISPR Therapeutics also falling 10%. Intellia paused dosing and enrollment following the Grade 4 liver event and is consulting regulators on next steps.
27 October 2025
···
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead shares closed near $123 on Oct. 17, 2025, up 4.2% and close to 52-week highs, after extending Biktarvy’s U.S. exclusivity to 2036 and securing a CDC endorsement for Yeztugo. Q2 earnings beat forecasts, prompting raised guidance and analyst upgrades. Gilead is set to present positive Phase 3 Trodelvy data at ESMO and is expanding cell therapy with a $350M Interius BioTherapeutics deal.
18 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics shares surged over 30% to $89.19 on Oct. 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The jump follows positive Phase 2b results for Icotrokinra in ulcerative colitis and recent FDA Breakthrough Therapy Designation for Rusfertide in polycythemia vera.
10 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer shares surged 15% from Sept. 26 to Oct. 1, closing at $27.21 after a major drug-pricing deal with the Trump administration. The agreement, announced Sept. 30, ties U.S. Medicaid prices to those in other wealthy countries in exchange for tariff relief. Pfizer also agreed to buy obesity-drug developer Metsera for $4.9 billion. Market cap stands near $155 billion, with a dividend yield around 6%.
2 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer shares closed at $23.60 on Sept. 25, 2025, down 9% year-to-date and 18% from a year ago, near the bottom of their 52-week range. The dividend yield has risen above 7% as the stock slumped. In September, Pfizer announced a $7.3 billion acquisition of Metsera and reported strong Phase 3 results for a new COVID-19 vaccine. A key court hearing on Depo-Provera lawsuits is set for Sept. 29.
26 September 2025
···
1 … 7 8 9

Stock Market Today

  • Planet Labs Nears Sustainable Profitability Amid Industry Challenges
    May 21, 2026, 3:12 PM EDT. Planet Labs (PL) operates a vast network of Earth observation satellites capturing global images daily. Despite technological advances and expanded roles in defense and agriculture, the company has yet to secure steady profits due to high costs in satellite manufacturing, launches, maintenance, and R&D. Revenue growth lags behind fixed costs, while long government sales cycles delay cash flow. Management's 2026 guidance shows optimism, focusing on cost control, vertical specialization, and software monetization to enhance margins. Industry peers Rocket Lab (RKLB) and BlackSky Technology (BKSY) face similar profitability challenges. PL's stock has surged 117% year-to-date but trades at a lofty price-to-sales ratio of 31.38, far above the industry average of 3.86, reflecting high investor expectations amid ongoing financial pressures.

Latest articles

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

21 May 2026
Nebius Group N.V. shares surged 15.6% to $221.72 after announcing a fuel cell power deal with Bloom Energy, securing up to 328 MW of on-site electricity capacity for its AI infrastructure. The agreement could cost Nebius up to $2.6 billion over 10 years. Bloom shares rose 12.2% on the news. Nebius's first-quarter revenue jumped to $399 million from $50.9 million a year earlier.
Sirius XM stock nears new highs as traders look at audio strategy

Sirius XM stock nears new highs as traders look at audio strategy

21 May 2026
Sirius XM shares rose 6.8% to $28.90 by 2:07 p.m. EDT Thursday, outpacing major U.S. indexes. The rally followed CFO Zac Coughlin’s investor conference appearance and news of a renewed multi-year NASCAR broadcast deal. First-quarter subscriber losses were smaller than expected, and revenue topped forecasts. Volume reached 4.8 million shares, with a market value near $9.8 billion.
KEEL Surges as Investors Back Keel’s AI Data Center Plans

KEEL Surges as Investors Back Keel’s AI Data Center Plans

21 May 2026
Keel Infrastructure shares jumped 7.1% to $4.53 Thursday, nearing a 52-week high, as investors bet on its pivot from crypto mining to AI-focused power infrastructure. Trading volume reached 22.31 million shares, below average. The company reported a wider net loss of $145.35 million for the March quarter on lower revenue and warned its transformation faces risks tied to permits, costs, and competition.
Go toTop